NATCO Pharma Ka Dhamakedar Launch! Generic Semaglutide ₹1,290 Mein, Diabetes/Obesity Patients Ke Liye Badi Khushkhabri!

HEALTHCAREBIOTECH

Overview

Arre bhai, NATCO Pharma ne India mein apna generic Semaglutide launch karne ka announce kiya hai, woh bhi March 21, 2026 se! Sabse badhiya baat ye hai ki ye bohot affordable hoga, type 2 diabetes aur obesity ke liye bohot faydemand hone wala hai.

CDSCO Ne Diya Green Signal!

NATCO Pharma ko February 2026 mein India ki Central Drugs Standard Control Organisation (CDSCO) se approval mil gaya hai generic Semaglutide banane aur bechne ke liye. Clinical studies mein bhi ye prove ho gaya hai ki ye original dawa jaisa hi kaam karta hai. Ab company India mein pehli baar affordable GLP-1 therapy launch karne ke liye ready hai.

Sasti Dawa, Bada Impact!

Is dawa ko do brands ke naam se launch kiya ja raha hai – SEMANAT™ aur SEMAFULL™. Diabetes aur obesity ke advanced treatments ab sabke liye accessible honge. Multi-dose vials ke liye mahine ka kharcha sirf ₹1,290 hoga (2mg/1.5ml aur 4mg/3ml doses ke liye), aur 8mg/3ml dose ke liye ₹1,750 hoga. Jo pen device versions aayenge April 2026 mein, unki price ₹4,000 se ₹4,500 ke beech rahegi. Ye price existing pen devices se 70% tak kam hai aur originator brands se toh lagbhag 90% tak sasti padegi!

Stock Mein Bhi Dikhi Tezi!

Is launch ki khabar sunte hi NATCO Pharma ke stock mein bhi tezi dikhi. March 20, 2026 ko share 3.06% badh kar ₹966.80 par trade kar raha tha. Is saal ab tak stock 8.26% upar hai aur pichhle ek saal mein 16.40% badha hai. Analysts ko lagta hai ki ye launch company ke future growth ke liye bohot acha rahega.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.